Recently, Fang et al. identified a compound 24s, which has good selectivity targeting JMJD2D and significantly suppresses the proliferation and migration of CRC cells [119], and may have the potential to be developed to a specific JMJD2D inhibitor or a JMJD2D-specific targeting drug. This evidence concerns the gene KDM4D and colorectal carcinoma.